Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro

Cancer Immunology, Immunotherapy

Volumn 58, Issue 10, 2009, Pages 1647-1655

  Liu, Wujiang ^a   O'Donnell, Michael A ^a   Chen, Xiaohong ^a   Han, Ruifa ^b   Luo, Yi ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Tainjin Institute of Urology   (China)

Author keywords

BCG; Bladder cancer; Cytotoxicity; IFN

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN;

ARTICLE; BLADDER TUMOR; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; NATURAL KILLER CELL; PATHOLOGY; TUMOR CELL CULTURE;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON ALFA-2B; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 68549123471     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0673-z     Document Type: Article

References (49)

1. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124:38-40
2. O'Donnell MA, DeWolf DC (1995) Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 4:189-202
3. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689-1694 (Pubitemid 29224536)
4. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53-58 (Pubitemid 20221267)
5. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636-1642
6. Peuchmaur M, Benoit G, Vieillefond A, Chevalier A, Lemaigre G, Martin ED, Jardin A (1989) Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 17:299-303 (Pubitemid 19228627)
7. Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Diez Gil, de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int 88:602- 610
8. De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 33:411-416
9. De Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19:45-50
10. Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Elevations of cytokines interleukin-1, interleukin- 2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette- Guérin immunotherapy. J Urol 144:59-64 (Pubitemid 20221268)
11. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477-482 (Pubitemid 26023528)
12. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE (2000) Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 164:2129-2133
13. Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52:268-275
14. Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 131:206-216 (Pubitemid 36205130)
15. Luo Y, Chen X, O'Donnell MA (2007) Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147:370-378 (Pubitemid 46096016)
16. Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette- Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150:1932-1937 (Pubitemid 24350840)
17. Thanhäuser A, Böhle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD, Ulmer AJ (1995) The induction of bacillus-Calmette- Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40:103- 108
18. Thanhäuser A, Böhle A, Flad HD, Ernst M, Mattern T, Ulmer AJ (1993) Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37:105-111 (Pubitemid 23175045)
19. Brandau S, Böhle A, Thanhäuser A, Ernst M, Mattern T, Ulmer AJ, Flad HD (2000) In vitro generation of bacillus Calmette-Guérin- activated killer cells. Clin Infect Dis 31(Suppl 3):S94-S100 (Pubitemid 32269598)
20. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette- Guérin-activated killer cells. Clin Cancer Res 6:3729-3738
21. Platts KE, Lawry J, Hancock BW, Rees RC (1993) Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3. Exp Cell Res 208:154- 160
22. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK (1998) Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 26:155-159 (Pubitemid 28305378)
23. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573-580
24. Dejager R, Guinan P, Lamm D (1991) Long-term complete remission in bladder carcinoma in situ with intravesical tice bacillus Calmette- Guérin. Urology 38:507-513
25. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147:596-600
26. Bercovich E, Deriu M, Manferrari F, Irianni G (1995) BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 67:257-260
27. Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R (1996) Bacillus Calmette-Guérin plus intravesical interferon alpha- 2b in patients with superficial bladder cancer. Urol 48:957-961
28. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA (1999) IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 162:2399-2405 (Pubitemid 29288868)
29. Joudi FN, Smith BJ, O'Donnell MA, National BCG-interferon phase 2 investigator group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344-348 (Pubitemid 43963411)
30. Luo Y, Chen X, O'Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 21:17-26 (Pubitemid 36369372)
31. Chen X, O'Donnell MA, Luo Y (2007) Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol 149:178-185 (Pubitemid 46897114)
32. Zhang Y, Khoo HE, Esuvaranathan K (1999) Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 161:977-983 (Pubitemid 29422419)
33. Pryor K, Stricker P, Russell P, Golovsky D, Penny R (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41:309-316 (Pubitemid 26008823)
34. Luo Y, Chen X, Han R, O'Donnell MA (2001) Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264-270 (Pubitemid 32174778)
35. O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508-2514 (Pubitemid 24157083)
36. Brandau S, Böhle A (2001) Activation of natural killer cells by bacillus Calmette-Guérin. Eur Urol 39:518-524 (Pubitemid 32678965)
37. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Böhle A (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92:697-702 (Pubitemid 32385713)
38. Suttmann H, Jacobsen M, Reiss K, Jocham D, Böhle A, Brandau S (2004) Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172:1490-1495 (Pubitemid 39249755)
39. Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H (2007) Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int J Urol 14:532-538 (Pubitemid 46985528)
40. Biron CA (2001) Interferons alpha and beta as immune regulators - a new look. Immunity 14:661-664
41. Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM (2000) Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 80:197-207
42. Matsumoto H, Suzuki K, Tsuyuguchi K, Tanaka E, Amitani R, Maeda A, Yamamoto K, Sasada M, Kuze F (1997) Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun 65:4405-4410 (Pubitemid 27463204)
43. Esin S, Batoni G, Pardini M, Favilli F, Bottai D, Maisetta G, Florio W, Vanacore R, Wigzell H, Campa M (2004) Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 112:143-152 (Pubitemid 38609832)
44. + T cells to enhance priming for interferon- γproduction and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90:10188-10192
45. Mizel SB (1989) The interleukins. FASEB J 3:2379-2388
46. Alvarez-Mon M, Moltó LM, Manzano L, Olivier C, Carballido JA (1992) Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs 3(Suppl 1):5-8
47. Moltó L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C, Rodriguez-Zapata M (1994) Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 70:1247-1251 (Pubitemid 24358971)
48. Mitropoulos DN (2005) Novel insights into the mechanism of action of intravesical immunomodulators. In Vivo 19:611-621
49. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon- alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-2734 (Pubitemid 29493945)